Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tedopi (OSE Immunotherapeutics)
- Development stage
- Unknown
- Lead developer
- OSE Immunotherapeutics
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
**Tedopi** is an investigational, off-the-shelf, multi-peptide therapeutic cancer vaccine developed by OSE Immunotherapeutics. Also known as OSE2101, it contains nine HLA-A2-restricted tumor-antigen epitopes plus the universal helper T-cell epitope PADRE, designed to induce tumor-specific cytotoxic and helper T-cell responses against carcinoembryonic antigen, HER2, MAGE2, MAGE3, and p53. It is being evaluated principally in HLA-A2-positive advanced or metastatic non-small cell lung cancer with secondary resistance to PD-1 or PD-L1 checkpoint inhibition; the confirmatory ARTEMIA registration trial is ongoing in Phase 3. ([ose-immuno.com](https://www.ose-immuno.com/en/our-products/tedopi-modular/))
- Brand names
- Tedopi
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)TP53 (Cellular Tumor Antigen p53 R175H)ERBB2 (Erb-b2 receptor tyrosine kinase 2)MAGEA2 (Melanoma-associated antigen 2)MAGEA3 (Melanoma-associated antigen 3)
Beyond the preview
Go deeper on Tedopi (OSE Immunotherapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tedopi (OSE Immunotherapeutics).